ArticleJournal of healthcare engineering2022
Analysis on Value of Applying Serum miR-144 and miR-221 Levels in Diagnosing Atherosclerosis.
Article in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Oxidative Stress Modulation by ncRNAs and Their Emerging Role as Therapeutic Targets in Atherosclerosis and Non-Alcoholic Fatty Liver Disease.Antioxidants (Basel, Switzerland) · 2023Review
- Retracted: Analysis on Value of Applying Serum miR-144 and miR-221 Levels in Diagnosing Atherosclerosis.Journal of healthcare engineering · 2023Article
Corrections and comments
- Retraction · 2023-01-30Concerns/Issues about Peer Review · Investigation by Journal/Publisher ·
- Retracted
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the value of serum miR-144 and miR-221 in diagnosing atherosclerosis (AS).
methodsThe clinical data of 52 AS patients treated in the department of cardiovascular medicine of our hospital from August 2019 to August 2020 were retrospectively analyzed, and 53 healthy persons were selected from the physical examination center at the same period as the control group. By measuring the indicators including the serum vascular endothelial growth factor (VEGF), superoxide dismutase (SOD), miR-144, and miR-221 in patients of both groups, their value of diagnosing AS was analyzed.
resultsCompared with the control group, the AS group obtained significantly higher serum miR-221 and miR-144 expression levels (
conclusionSerum miR-221 and miR-144 expression levels are increased in AS patients, and combining the two indicators in diagnosis is more accurate and can provide an accurate basis for diagnosis and condition assessment of AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.